HPD Research Day | February 16, 2018

55 Objectives. To assess student satisfaction of a structured co-curricular program designed to increase guidance in selecting experiences that foster personal and professional development. Background. Accreditation standards require the establishment of a co-curricular program to expose students to various types of Pharmacy practice. Method. Students were required to complete a minimum of 7 co-curricular activities divided between 5 specific areas of professional growth. P1 students completed an anonymous 17-item on-line questionnaire at the end of the first semester. A five-point Likert scale measured: impact on personal/professional growth, value of the experiences, development of problem solving skills, ability to work as a team member, interaction with other healthcare professionals and cultural awareness. Barriers to completing co-curricular experiences were also addressed. Results. 199 students, 67.3% female, 31.7% male and 1% gender neutral completed the questionnaire (74% response rate). 81% of students found the experiences helped them grow as a person/professional; 73% found the co-curricular experiences to be of value; 60% reported that their ability to problem solve increased and 79% stated that their ability to work as part of a team improved. 87% indicated co-curricular experiences allowed interaction with other healthcare professionals and 75% reported improved knowledge of individuals from other races/cultures. Academic obligations were the most common barrier to completing co-curricular experiences. Overall, 73% of students would complete co-curricular activities if not required. Implications. A co-curricular program structured to provide experiences focusing on personal/ professional growth is valued by students and promotes growth in these areas. Grants. None Atrium – Poster 52 12:15-1:15 p.m. Modulation of Angiotensin II Binding and AT1 Receptor Expression in Experimental Alport Mouse Kidney Christopher T. Neagra, DO, Palmetto General Hospital, Hialeah, FL Hong Weng Pang, College of Pharmacy, Nova Southeastern University Andrea Linares, College of Pharmacy, Nova Southeastern University Judith T Molina-David, University of Miami Alessia Fornoni, University of Miami Robert Charles Speth, Ph.D., Professor, College of Pharmacy, Nova Southeastern University Objective. To measure AT 1 angiotensin II (AngII) receptor (AT1R) expression in an animal model of Alport Syndrome (AS) to assess the association between these receptors and this disease. Background. AS is a progressive renal glomerular disease, causing kidney failure, and hearing and visual impairment, affecting up to 3% of children and 0.2% of adults with end-stage renal disease (ESRD). It is caused by mutation of a Type IV collagen gene. Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) are the only treatments that slow progression towards ESRD in AS. Methods. Kidneys from 8-week-old Col4a3-/- (KO) and wild-type mice were assayed for AT1R using 125 I-sarcosine 1 ,isoleucine 8 AngII saturation binding assay and receptor autoradiography to determine receptor density, distribution and binding affinity. Results. There was a 48% decrease (pDvalues did not differ between the groups. Receptor autoradiography showed no difference in AT1R density between the groups (153 versus 149 fmoles/g wet weight). However, AT1R’s were more diffusely distributed in the KO kidneys. Conclusion. The density of AT1 receptors in the AS model kidney is reduced. This suggests that renoprotection with ACEi-ARB in AS is not linked to overexpression of renal AT1R. Funding. Peggy and Harold Katz Family Endowed Professorship (AF), Cardiovascular Neuroscience Fund. Atrium – Poster 53 12:15-1:15 p.m. A Case of Progressive Optic Neuropathy in a Patient with Wegener’s Granulomatosis Leon Nehmad, OD, Professor, College of Optometry, Nova Southeastern University Jessica Siu, College of Optometry, Nova Southeastern University Introduction. We describe a case of a patient with Wegener’s Granulomatosis (WG) who developed progressive optic atrophy and worsening of vision despite treatment. Case presentation. A 46 year old Hispanic male presented with complaints of blurry vision OD>OS. He had been diagnosed with WG 3 months earlier and after experiencing multiple symptoms, was stabilized on prednisone. VA was 20/15 in each eye, C/D ratios were .20 OU with sectoral pallor OD, moderate retinal nerve fiber layer (RNFL) loss OD on OCT, and retinal vascular changes OU. Visual fields showed generalized depression OD and arcuate defect OS. At a 5-month follow up visit, he complained of